Drug Trial Radar · NCT00076232
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Last checked: Nov 19, 2026Latest source record: Dec 30, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,682
Planned (sponsor's estimate)
Start
Apr 2005
Primary completion
Jun 2007
Study completion Nov 2007
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
- First posted
- Jan 16, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Prevention
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence of genital sores is a significant risk factor for becoming infected with HIV. This study will test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men who sleep with men (MSM). Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition, twice-daily HSV-2 suppressive therapy - 400 mg of acyclovir - will prevent HIV infection among high risk, HSV-2 seropositive WSM and MSM.
Conditions
- HIV Infections
- HIV Seronegativity
- Herpes Genitalis
Interventions
AcyclovirDrug
400 mg tablet taken orally twice daily
Acyclovir placeboDrug
Oral tablet taken twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serologically confirmed HIV infectionTime frame: Throughout study
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
San Francisco Department of Public Health, AIDS Office, Research Section
San Francisco, California
New York Blood Center
New York, New York
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.